Stoke Therapeutics, Inc. STOK Business Segments
| FY'25 | FY'24 | ||
|---|---|---|---|
| Revenue by Product | |||
| Global Development Activity | $17.49M— | —— | |
| IP License | $150.78M— | —— | |
| License | $11.5M-60.9% | $29.4M— | |
| Service | $4.6M-36.1% | $7.2M— | |
| Operating Expenses by Product | |||
| ADOA | -$6.16M+16.9% | -$7.41M+9.0% | |
| MECP2 | $37K+103% | -$1.07M-7.5% | |
| Other External Program Costs | -$8.84M-0.7% | -$8.77M+11.0% | |
| Other Non Program Costs Research And Development | -$6.15M-15.5% | -$5.33M-42.2% | |
| Payroll And Other Personnel Costs Research And Development | -$51.71M-38.1% | -$37.45M-16.1% | |
| SYNGAP1 | -$3.33M-153% | -$1.32M-138% | |
| Zorevunersen | -$71.83M-125% | -$31.99M-14.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Stoke Therapeutics, Inc. break its business down?
- Stoke Therapeutics, Inc. (STOK) reports revenue by product across 4 parts — Global Development Activity, IP License, License and Service. Each is extracted from the segment footnotes and tracked over time.
- Where does Stoke Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Stoke Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.